Share

June 2017; 7 (3) Review

The financial contribution of the multiple sclerosis specialist

Joseph R. Berger
First published May 10, 2017, DOI: https://doi.org/10.1212/CPJ.0000000000000360
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
342

Share

Article Information

vol. 7 no. 3 246-255
DOI: 
https://doi.org/10.1212/CPJ.0000000000000360
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received December 3, 2016
  • Accepted February 8, 2017
  • First Published May 10, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Joseph R. Berger, MD
  1. Joseph R. Berger, MD
    2. Scientific Advisory Boards:

    1. Dr. Berger has served as a consultant and/or on the PML adjudication committees of Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Janssen, Parexel, and Pfizer. He also serves on the Scientific Advisory Board of NeuVir and ExcisionBio.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Berger has received honoraria from Prime Education and the MS Foundation for lectures.

    Editorial Boards:

    1. Dr. Berger serves as an Associate Editor for the Journal of Neurovirology, serves as an editorial board member of ISRN Education, Neuroscience, World Journal of Rheumatology and MS and other related disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. Portegies P, Berger JR (Editors): HIV/AIDS and the Nervous System. In Vinken PJ, Bruyn G (Editors): Handbook of Clinical Neurology, Volume 85; Elsevier, Amsterdam, 2007.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Berger has served on a consultant to Alcimed, Amgen, AstraZeneca, Bayer, Biogen, Eisai, EMD Serono, Forward Pharmaceuticals, Genentech/Roche, Genzyme, Inhibikase, Millenium/Takeda, Novartis, Johnson and Johnson, Pfizer, and Sanofi Aventis.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Biogen

  1. Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  1. Correspondence to:
    joseph.berger{at}uphs.upenn.edu
View Full Text

Article usage

Article usage: May 2017 to April 2022

AbstractFullPdfSource
May 201712203Highwire
Jun 20175871677Highwire
Jul 2017393634Highwire
Aug 2017580619Highwire
Sep 2017295228Highwire
Oct 2017189326Highwire
Nov 201710512Highwire
Dec 20177548Highwire
Jan 20181131111Highwire
Feb 20187165Highwire
Mar 201810156Highwire
Apr 20184665Highwire
May 201868710Highwire
Jun 20186676Highwire
Jul 20185043Highwire
Aug 20189264Highwire
Aug 20188109pmc
Sep 20185492Highwire
Oct 201810674Highwire
Nov 20187684Highwire
Dec 20186953Highwire
Jan 20195552Highwire
Feb 2019114179Highwire
Mar 2019207114Highwire
Apr 201926560Highwire
May 201923741Highwire
Jun 201928465Highwire
Jul 201939932Highwire
Aug 201960020Highwire
Sep 201952965Highwire
Oct 201951832Highwire
Nov 201937046Highwire
Dec 201919910Highwire
Jan 20203122Highwire
Feb 20202821Highwire
Mar 20201820Highwire
Apr 20209401Highwire
May 202021401Highwire
Jun 20202221Highwire
Jul 20201811Highwire
Aug 20203920Highwire
Sep 20204400Highwire
Oct 20203900Highwire
Nov 20202131Highwire
Dec 20203234Highwire
Jan 20212431Highwire
Feb 20214021Highwire
Mar 20214331Highwire
Apr 20213310Highwire
May 20215412Highwire
Jun 20212031Highwire
Jul 20213501Highwire
Aug 20215140Highwire
Sep 20213221Highwire
Oct 20214454Highwire
Nov 20211712Highwire
Dec 20212921Highwire
Jan 20224012Highwire
Feb 20223425Highwire
Mar 20223013Highwire
Apr 20222300Highwire

Cited By...

The Nerve!: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me